Higher Metrnl was associated with lowered CAD onset and severity, which is likely owed to Metrnl serving as an anti-oxidative factor against ROS production, in turn downregulating NLRP3 inflammasome activity and subsequent production of inflammatory cytokines, as well as counteracting against palmitic acid (PA)-induced endothelial glucose metabolic dysfunction in vitro, both of which otherwise contribute to the formation of atherosclerotic plaques. Here, NLRP3 is linked to coronary artery disorder.